FineHeart

Executive Summary

FineHeart is a clinical-stage medical technology company developing the ICOMS Flowmaker®, an innovative intra-cardiac pump designed to augment the native function of the heart in patients with advanced heart failure. Based in Bordeaux, France, the company addresses a significant unmet clinical need with its active implantable device that could offer a less invasive alternative to traditional left ventricular assist devices (LVADs). The ICOMS Flowmaker is positioned to improve hemodynamics and patient quality of life, with potential to capture a sizable market in the growing heart failure space. FineHeart has completed preclinical studies and is advancing into early clinical phases, with a focus on safety and feasibility. The company's proprietary technology and strong IP position could attract strategic partnerships or acquisition interest from larger cardiovascular players. Given the high unmet need and innovative approach, FineHeart represents a compelling opportunity in the medtech sector, though it remains early-stage with execution risks.

Upcoming Catalysts (preview)

• Q2 2026Initial clinical trial results (Phase I feasibility study)60% success
• Q4 2026Regulatory clearance for expanded clinical study (CE mark or IDE)70% success
• Q1 2027Strategic partnership or licensing deal with a major cardiovascular device company40% success